GLP-1 medications may help colon cancer patients live longer by reducing inflammation and improving metabolic health, UC San ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...

The study found that the five-year mortality rate was significantly lower among patients who were using GLP-1 receptor ...

GLP-1 receptors - the drugs behind Ozempic and Mounjaro - could have great benefits for colon cancer patients, the study ...

People with colon cancer who took GLP-1 drugs were less likely to die within 5 years than people not on GLP-1s, a new study ...

While drugs like Wegovy, Ozempic and Mounjaro are hailed for regulating blood sugar and helping people lose weight, new ...

Bowel-related symptoms persist for up to 5 years after colorectal cancer, and higher dietary fiber intake is associated with ...

Medications like Wegovy and Ozempic, known for managing diabetes and promoting weight loss, may also be linked to ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.

5 young colon cancer patients share their stories, including their missed symptoms, their diagnosis, and their advice on how to save yourself ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...